Novel Approaches and Challenges of Discovery of Exosite Modulators of a Disintegrin and Metalloprotease 10
Copyright © 2020 Minond..
A disintegrin and metaproteinase 10 is an important target for multiple therapeutic areas, however, despite drug discovery efforts by both industry and academia no compounds have reached the clinic so far. The lack of enzyme and substrate selectivity of developmental drugs is believed to be a main obstacle to the success. In this review, we will focus on novel approaches and associated challenges in discovery of ADAM10 selective modulators that can overcome shortcomings of previous generations of compounds and be translated into the clinic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Frontiers in molecular biosciences - 7(2020) vom: 11., Seite 75 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Minond, Dmitriy [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ADAM10 |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fmolb.2020.00075 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310179831 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310179831 | ||
| 003 | DE-627 | ||
| 005 | 20231225135528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmolb.2020.00075 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM310179831 | ||
| 035 | |a (NLM)32435655 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Minond, Dmitriy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel Approaches and Challenges of Discovery of Exosite Modulators of a Disintegrin and Metalloprotease 10 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020 Minond. | ||
| 520 | |a A disintegrin and metaproteinase 10 is an important target for multiple therapeutic areas, however, despite drug discovery efforts by both industry and academia no compounds have reached the clinic so far. The lack of enzyme and substrate selectivity of developmental drugs is believed to be a main obstacle to the success. In this review, we will focus on novel approaches and associated challenges in discovery of ADAM10 selective modulators that can overcome shortcomings of previous generations of compounds and be translated into the clinic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ADAM10 | |
| 650 | 4 | |a drug discovery | |
| 650 | 4 | |a exosite | |
| 650 | 4 | |a glycosylation | |
| 650 | 4 | |a inhibitors | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in molecular biosciences |d 2014 |g 7(2020) vom: 11., Seite 75 |w (DE-627)NLM249149435 |x 2296-889X |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2020 |g day:11 |g pages:75 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fmolb.2020.00075 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2020 |b 11 |h 75 | ||